Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study)

Clinical trial evidence supports the use of intensive statin therapy for patients with coronary artery disease. High doses of potent statins have shown the greatest clinical benefit, but concerns persist regarding the efficacy and safety of achieving very low levels of low-density lipoprotein (LDL)...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2009-07, Vol.104 (1), p.29-35
Main Authors: Wiviott, Stephen D., MD, Mohanavelu, Satishkumar, MS, Raichlen, Joel S., MD, Cain, Valerie A., MS, Nissen, Steven E., MD, Libby, Peter, MD
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular
Cardiovascular disease
Cholesterol, VLDL - drug effects
Comparative analysis
Coronary Artery Disease - drug therapy
Coronary Artery Disease - physiopathology
Female
Fluorobenzenes - adverse effects
Fluorobenzenes - therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hyperlipidemias - drug therapy
Hyperlipidemias - physiopathology
Low density lipoprotein
Male
Medical sciences
Middle Aged
Prospective Studies
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Regression analysis
Rosuvastatin Calcium
Statins
Statistics, Nonparametric
Sulfonamides - adverse effects
Sulfonamides - therapeutic use
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trial evidence supports the use of intensive statin therapy for patients with coronary artery disease. High doses of potent statins have shown the greatest clinical benefit, but concerns persist regarding the efficacy and safety of achieving very low levels of low-density lipoprotein (LDL) cholesterol. We grouped patients treated with 40 mg of rosuvastatin daily by the LDL cholesterol achieved according to previous work (
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2009.02.040